NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT02591095 2019-03-19
MONAVI-1
Centre Francois Baclesse
Phase 2 Completed
NCT01828476 2017-05-04
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT01087151 2016-11-02
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 2 Completed
NCT01423539 2016-11-02
NAVIGATE
Genentech, Inc.
Phase 2 Withdrawn